New clinical trial opportunities
RareCan is actively screening people with multiple myeloma for clinical trials. If you have MM, we’d really like to hear from you.
Click the button below to get started.
Partnership with Blood Cancer UK
RareCan’s partnership with Blood Cancer UK has enabled the growth of its patient membership with specific types of blood cancers such as multiple myeloma. This is helping RareCan to quickly grow its cohorts and deliver its screening process to assist the rapid delivery of clinical trials focussed on the prevention, diagnosis, or treatment of blood cancers.
Multiple myeloma (MM)
For a much more detailed guide, please read our multiple myeloma information pack.
Also known as:
- Plasma cell myeloma
- Kahler’s Disease
What is multiple myeloma?
Multiple Myeloma is a rare cancer that affects the plasma cells. These are the cells responsible for producing the antibodies that help to protect against infection.
How rare is multiple myeloma?
It occurs in about 10 in 100,000 people. Around 4,800 people are diagnosed with MM in the UK each year.
Who does multiple myeloma affect?
MM usually occurs at around the age of 60 and affects men more than women. It is uncommon before the age of 40.
Why is RareCan interested in multiple myeloma?
RareCan is working to accelerate research into multiple myeloma by making it easier for researchers to connect with people who have this rare form of cancer. You can help us do this by becoming a RareCan member and sharing information with us about your myeloma diagnosis. We will then get in touch with you about any research opportunities that might be suitable for you.
If you have multiple myeloma and are looking for support, we recommend the following websites:
Blood Cancer UK
Blood Cancer UK is a community dedicated to funding research and support for those affected by blood cancers like multiple myeloma.
Myeloma UK is a charity whose ultimate goal is to find a cure for myeloma. It is dedicated to improving standards of treatment and care through research, education and by raising awareness of myeloma.